Print

Global OTC Analgesics Review 2012: Discover pockets of potential in a challenging market

Published 29/01/2013

Author: Nicholas Hall Reports

The global OTC Analgesics market presents a varied and challenging environment for marketers looking to discover the pockets of high growth hidden in its relatively flat overall performance: expanding by just 2.5%, it was the slowest-growing major OTC category in the 12 months to mid-2012. Understanding the latest consumer trends and keeping up with recent innovations are vital if marketers are to overcome ongoing challenges such as a recessionary environment, strong generic competition and safety concerns over key ingredients, all of which form barriers to growth.

With virtually all the major OTC companies boasting a significant presence, and many smaller players exploiting the gaps, the analgesics market is highly competitive, but with plenty of potential.

This report will investigate areas including:
  • Developments in delivery formats such as massage roll-ons, easy applicators, liquid gels and effervescent formats
  • Marketers’ focus on “speed of action” and “increased strength” in promotion and new launches
  • Expansion of analgesic niches such as migraine, foot pain, dental pain, etc.
  • Trend towards on-the-go pack sizes
  • Performance of OTC triptans and what the future holds
  • Safety concerns over key ingredients, plus a look at the US FDA’s stance on topical pain relievers
  • Innovations (Botox for migraine, venom-based analgesics, etc.)
  • Analysis of sales performance, A+P efforts and innovation for key brands & marketers

This comprehensive report scrutinises the Analgesics market from a global level right down to individual countries, strategically analysing the trends & developments affecting brands, consumers and marketers.
  • Each country profile contains a detailed overview, key OTC growth drivers, regulatory issues, switches, A+P examples and prospects for the future.
  • Summary boxes offer succinct overviews of key developments & trends, while the detailed analysis drills down to individual brand level.
  • Charts cover OTC sales up to mid-2012, with growth rate analysis, leading marketers, top brands (overall and within each category) and sales forecasts to 2016 and 2021.

NEW!
  • DB6 OTC sales to mid-2012 in all major markets, from category toplines down to individuals marketers & brands.
  • 5 Key trends in Analgesics – summary boxes at the start of each country profile offer a concise overview of the main developments and core drivers of OTC growth.





DescriptionCountry LicenceGlobal LicenceBuy Country LicenceBuy Global Licence 
+ Analgesics Review 2012 Full Report £4,950.00 £6,500.00 Clear